Large multi-center Phase 3 human clinical trials testing efficacy, absolute risk reduction, and adverse-event rates against placebo or active gold-standard comparators. Every study summary reports the trial design, participant sample size (N), primary outcome highlight, and direct link to the formal NCBI PubMed or federal record.
The Plain-English Receipt: Only 1.2% of prediabetic adults on Tirzepatide progressed to Type 2 diabetes over 3.4 years vs. 19.3% on placebo (Absolute Risk Reduction = 18.1% • Number Needed to Treat = 6).
Over 96 weeks, including Study MT-1186-A02, daily dosing did not show a statistically significant difference vs.
Dentifrice containing 8.0% arginine showed a statistically significant reduction in caries incidence versus the NaF control, while the 1.5% arginine dentifrice showed equivalence to the NaF control regarding caries reduction.
Low-dose triple single-pill combination of telmisartan/amlodipine/chlorthalidone demonstrated superior BP-lowering efficacy with well-tolerated and comparable safety to standard-dose telmisartan single-drug treatment.
Over 152 weeks, patients stably maintained and extended their regrowth across scalp, eyebrows, and eyelashes with continued baricitinib treatment.
Females were younger (mean age: 42.9 vs.
Daridorexant warrants further investigation in COMISA.
This is the only heart and blood vessel outcomes trial to date that exclusively enrolled patients with statin intolerance, and the largest contemporary study of lipid lowering therapy in females, a group historically...
This analysis confirmed the reliability and validity of the PESQ-C for evaluating caregiver-observed EoE signs in children patients within a clinical study context.
In summary, deutenzalutamide significantly prolonged rPFS and, after adjustment, showed a potential OS benefit with a favorable safety profile, supporting its promise as a new treatment option for mCRPC.
In 387 subjects, among endoscopically active subjects (MES 2, 3), the CDS was lower in those achieving PMS symptomatic full symptom relief (83.8 vs 186.9, P < 0.0001).
These associations varied according to women’s socioeconomic status and municipality class.
Perfluorohexyloctane was well tolerated and improved the signs and symptoms of DED associated with MGD in patients with different baseline disease severity compared to saline control.
Under the current EV71 epidemic conditions in China, the two-dose regimen of the inactivated EV71 vaccine provides durable protection exceeding 72% for at least 20 years.
A high proportion of unvaccinated HIV-negative MSM with a new intra-anal 9vHPV infection developed same-type HPV-associated anal disease.
Simufilam did not meet co-primary or secondary endpoints in these Phase 3 trials.
Compared with conventional OST, the mini S-OST split dose showed excellent efficacy, comparable safety and tolerability, with less gastric injury (ClinicalTrial.gov identifier NCT06287606).
Secondary outcomes will include: symptomatic intracerebral hemorrhage, extracranial bleeding of any type, NIHSS at baseline and after 7 days, modified Rankin Scale at 3 months, serious thromboembolic side effects (including...
These results support the novel perioperative durvalumab regimen for patients with resectable NSCLC from the AEGEAN study, and no dose adjustment is necessary based on the PopPK and ER analyses.
T-Glu demonstrated similar immunogenicity, efficacy, and safety to R-Glu in adults with T1DM, supporting its use as a biosimilar insulin glulisine.
Phlai was safe.
At 8 weeks, the least square (LS) mean (SE) change in msSBP was -20.04 (1.46) mm Hg in the Tel/S-Amlo group, compared with -16.44 (1.46) mm Hg in the Tel group (between-group difference -3.60 (1.78) mm.
This study reports a high incidence (29%) of early-onset RIL in glioblastoma patients treated with the Stupp protocol, highlighting the question of individual sensitivity to this severe side effect.
The low-to-no change in obeldesivir susceptibility among the treatment-emergent Nsp12 substitutions indicates a high barrier to the development of obeldesivir resistance in high-risk, nonhospitalized patients with COVID-19.
Once-daily extended-release acetazolamide (500 mg) effectively prevents AMS and is well-tolerated in healthy Asian individuals.
FDCs significantly improved LDL-C goal attainment compared to AS single-drug treatment in patients with very high ASCVD risk.
For combined responses from 6MWD (% predicted) and FVC (% predicted), the odds of a better versus a lower response category (improvement > stability > worsening) were 4.05 (95 % confidence interval 1.73-9.51) times higher.
The low-to-no change in obeldesivir susceptibility among treatment-emergent Nsp12 substitutions indicated a high barrier to development of obeldesivir resistance in low-risk, nonhospitalized patients with COVID-19.
EXCAP may reduce CRCI and mental fatigue, particularly in patients receiving 2-week cycles of chemotherapy.
In HCV-related decompensated cirrhosis, 5 year LT-free survival rate after DAA was 74.7%, and viral clearance and post-treatment Child-Pugh class were associated with long-term prognosis.
Official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver (2026), this phase iii randomized trial evaluating human clinical outcomes investigated: The PRODIGE 85-FFCD...
Traditional health headlines often exaggerate findings by reporting only Relative Risk Reduction—for example, claiming a drug cuts risk by 50% when the event rate dropped from 2% to 1% (an Absolute Risk Reduction of just 1.0 percentage point, meaning 100 patients must take the drug for 1 person to benefit, or NNT = 100). On dotMD, every flagship study breakdown reports both Relative Risk and Absolute Risk alongside the exact sample size (N) and trial duration.
Every study on dotMD displays its exact Study Design Tier at the top of the card (Phase 3 Randomized Trial, Randomized Controlled Trial, Meta-Analysis & Systematic Review, Multi-Trial Clinical Evidence Synthesis, Journal Watch Cohort, or FDA Safety Alert) along with the human participant count (N). Preclinical mouse or cell-culture data is never presented as human clinical proof.
Arbitrary 0-to-100 rigor scores obscure what actually makes a study trustworthy. Instead of synthetic scores, dotMD surfaces the verifiable primary evidence signals: exact NCBI PubMed IDs (PMID), ClinicalTrials.gov registration numbers (NCT), double-blind vs. crossover design, sample size (N), p-values / Hazard Ratios, and study limitations.
Medical research is only useful if you can act on it safely with your clinician. Every flagship research synthesis links directly to the parent Condition diagnostic cutoff guide, the Medication FDA DailyMed & CMS NADAC wholesale price ledger, the Supplement elemental weight decoder, and our High-CPT-Volume Specialist Directory.
